Should Hims & Hers Stock's Drop After Earnings Worry You?
Hims & Hers Health (HIMS) stock dropped 16.6% after reporting Q3 2026 earnings. Revenue of $890M missed estimates by 2.2%, and EPS was -$0.10 vs. expected $0.06 profit. Subscribers fell by 100,000 to 2.8M. Management cut full-year EBITDA and revenue forecasts, citing marketing adjustments and delayed revenue recognition.
How this was made

The 30-second read
Why it matters
The earnings miss triggered a 16.6% intraday decline, highlighting execution risk in its weight‑loss segment.
Market read
The earnings surprise is the primary driver of the stock move and may influence peer valuations in the telehealth space.
What to watch
Free cash flow turned positive and international growth remains strong, which could mitigate the downside.
Background
Hims & Hers Health reported Q3 2026 results after market close, missing revenue and EPS expectations and cutting full‑year EBITDA guidance.
Ticker impact
Q3 2026 earnings miss and guidance cut caused a 16.6% share drop.
likely further downside as market prices in weaker revenue and margin outlook
Revenue fell short of estimates, EPS missed, margins compressed and guidance lowered, driving the sharp sell‑off.
Market effects
Weight‑loss and telehealth subsectors may see broader scrutiny after the miss.
U.S. small‑cap health tech stocks could face short‑term pressure.
Limited to investors tracking U.S. health‑tech earnings.
Counterpoint
The stock may be oversold; upcoming product launches could spark a rebound.
Key entities
- companyHims & Hers Health
U.S. telehealth and consumer wellness provider.



